CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D, providing an update on the company’s drug development pipeline targeting HIV and cancers, based on CytoDyn’s Leronlimab/PRO 140 platform.
H.C. Wainwright recently reiterated it’s BUY recommendation with a price target of $1.50 within 12 months.
CytoDyn’s combination therapy for HIV is expected to receive FDA approval in 2019, and potentially generating revenues by early 2020. Especially compelling is the possibility of CytoDyn’s HIV monotherapy which could get potential FDA approval the following year. CytoDyn’s monotherapy is a potential “game changer” in HIV treatment, requiring only a once-weekly injection which can be self-administered.
Dr. Pourhassan provides an update on CytoDyn’s recent news developments.
Research ReportHC Wainwright report
Investor PresentationCurrent Presentation